CSL Announces Full Year Results

CSL Strong Growth in Profit and Revenue

Melbourne, Australia — 15/08/2000

CSL Limited announces another year of strong growth in profits and revenues for 1999-00. Group sales rose 9% to $450.6m, producing a net profit after tax of $54.4m, an increase of 14.8% on the previous year’s result.

The Directors have declared a final dividend of 15c per share fully franked, payable on 12 October 2000. This will bring the total dividend for the year to 23c per share, representing a payout ratio of 61 per cent.

Managing Director, Dr Brian McNamee, said, "It is pleasing to report further strong growth for all business units in the Group. The underlying growth in sales, adjusted for the transition from the Australian Government's Factor (f) Scheme to the Pharmaceutical Industry Investment Programme (PIIP) was 12 per cent."

"Margins in CSL’s core activities, being Bioplasma products, Pharmaceutical and Veterinary vaccines, remain strong, with good growth in international sales, particularly JRH Biosciences, Inc. International sales now account for over 26 per cent of our total Group sales."

"Our international growth will be significantly enhanced in the forthcoming year through the acquisition of the ZLB business from a foundation affiliated to the Swiss Red Cross. Planning for ZLB’s integration into CSL’s operations is well advanced and we are looking forward to welcoming ZLB employees into the CSL group of companies."

The Board is pleased to announce the appointment of Tony Cipa to the Board as Finance Director.

For further information contact:

Dr Brian McNamee
Managing Director
Ph: +61 3 9389 1375

Mr Tony Cipa
Finance Director
Ph: +61 3 9389 1319

Group Results 1999/20002000
 Other revenue53.711.4
Total revenue504.3424.9
 Net interest expense(3.4)(1.6)
Pre-Tax Profit80.670.3
 Less Tax26.222.9
Net Profit54.447.4
Final Dividend (cents)15.014.0
EPS (cents)40.836.1
© 2017 CSL Limited